Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma

New England Journal of Medicine

Volumn 337, Issue 8, 1997, Pages 529-534

  Ichikawa, Atsushi ^a   Kinoshita, Tomohiro ^b   Watanabe, Takashi ^b   Kato, Hirokazu ^b   Nagai, Hirokazu ^b   Tsushita, Keitaro ^c   Saito, Hidehiko ^b   Hotta, Tomomitsu ^b  

^a GIFU PREFECTURAL TAJIMI HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; PROTEIN P53; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

AGED; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; REGRESSION ANALYSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0030818785     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199708213370804     Document Type: Article

References (46)

1. Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986;104:757-65.
2. Laurence J, Coleman M, Allen SL, Silver RT, Pasmantier M. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med 1982;97:190-5.
3. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985;102:596-602.
4. Longo DL, DeVita VT Jr, Duffey PL, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991;9:25-38. [Erratum, J Clin Oncol 1991;9:710.]
5. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
6. Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988;6:1838-44.
7. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
8. Coiffier B, Lepage E. Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. Blood 1989;74:558-64.
9. Jagannath S, Velasquez WS, Tucker SL, et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986;4:859-65.
10. Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991;9:211-9:
11. Fisher RI, Hubbard SM, DeVita VT, et al. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifterentiated lymphoma. Blood 1981;58:45-51.
12. Swan F Jr, Velasquez WS, Tucker S, et al. A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989;7:1518-27.
13. Pui CH, Ip SH, Kung P, et al. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 1987;70:624-8.
14. Schouten HC, Sanger WG, Weisenburger DD, Anderson J, Armitage JO. Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: associations with histology, clinical characteristics, and treatment outcome. Blood 1990;75:1841-7.
15. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
16. Hermine O, Haioun C, Lapage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996;87:265-72.
17. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994; 331:74-80.
18. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 Mutations in human cancers. Science 1991;253:49-53.
19. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-21.
20. Nigro JM, Baker Sf, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
21. Baker SJ, Preisinger AC, Jessup JM, et al. p53 Gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717-22.
22. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
23. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255:459-62.
24. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
25. Thorlacius S, Borresen AL, Eyfjord JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 1993;53:1637-41.
26. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
27. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
28. Ichikawa A, Hotta T, Takagi N, et al. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 1992;79:2701-7.
29. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35.
30. McKelvey EM, Gottlieb JA, Wilson HE. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484-93.
31. Rodriguez V, Cabanillas F, Burgess MA, et al. Combination chemotherapy ("CHOP-Bleo$) in advanced (non-Hodgkin) malignant lymphoma. Blood 1977;49:325-33.
32. Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988;6:128-41.
33. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6. [Erratum, J Clin Oncol 1990;8:1602.]
34. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990;10:5502-9.
35. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-9.
36. Suzuki Y, Sekiya T, Hayashi K. Allele-specific polymerase chain reaction: a method for amplification and sequence determination of a single component among a mixture of sequence variants. Anal Biochem 1990; 192:82-4.
37. Gyllensten UB, Erlich HA. Generation of single-stranded DNA by the polymerase chain reaction and its application ro direct sequencing of the HLA-DQA locus. Proc Natl Acad Sci U S A 1988;85:7652-6.
38. Armitage P. Statistical methods in medical research. 3rd ed. London: Blackwell Science, 1994.
39. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
40. Cox DR. The analysis of binary data. London: Chapman & Hall, 1970.
41. Idem. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-220.
42. Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997;89:601-9.
43. Vogelstein B, Kinzler KW. p53 Function and dysfunction. Cell 1992; 70:523-6.
44. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
45. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990;5:945-52.
46. Vogelstein B. Cancer: a deadly inheritance. Nature 1990;348:681-2.